Casdin Capital, a private equity firm, led a $100m Series B funding round in C2i Genomics, an American cancer intelligence company. The round also had participation from NFX, Duquesne Family Office, Section 32, iGlobe Partners and Driehaus Capital. Additional participation came from The Mark Foundation for Cancer Research, Silver Lake, Alexandria Real Estate, Gordon Asset Management and LionBird. C2i also plans to use the financing to strengthen its partnerships with pharma companies – leveraging C2 Intelligence’s superior sensitivity in detection to flag postsurgical patients for adjuvant therapy or a clinical trial and in immunotherapy.